Madrigal's MGL-3196 meets in Phase II NASH trial

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) reported top-line data showing that MGL-3196 (VIA-3196) met the primary endpoint in a Phase II trial to treat biopsy-proven non-alcoholic steatohepatitis (NASH).

On the 125-patient

Read the full 288 word article

User Sign In